NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF

The present invention relates to novel thienopyrimidine derivatives, to processes for the preparation thereof, and also to the therapeutic uses thereof, in particular as anticancer agents via ALK kinase inhibition.

The present invention also relates to pharmaceutical compositions containing these derivatives, which have anticancer activity via ALK kinase modulation.

At the current time, most commercial compounds used in chemotherapy are cytotoxic compounds which pose considerable problems in terms of side effects and tolerance by patients. These effects could be limited insofar as the medicines used act selectively on cancer cells, with exclusion of healthy cells. One of the solutions for limiting the adverse effects of chemotherapy can therefore consist of the use of medicines which act on metabolic pathways or constituent elements of these pathways, expressed predominantly in cancer cells, and which would be expressed little or not at all in healthy cells. Protein kinases are a family of enzymes which catalyze the phosphorylation of hydroxyl groups of specific residues of proteins, such as tyrosine, serine or threonine residues. Such phosphorylations can widely modify the function of proteins: thus, protein kinases play an important role in the regulation of a large variety of cell processes, including in particular metabolism, cell proliferation, cell adhesion and motility, cell differentiation or cell survival, some protein kinases playing a central role in the initiation, development and completion of cell cycle events.

Among the various cell functions in which the activity of a protein kinase is involved, certain processes represent attractive targets for treating certain diseases. As an example, mention may particularly be made of angiogenesis and control of the cell cycle and also the control of cell proliferation, in which processes protein kinases can play an essential role. These processes are in particular essential for the growth of solid tumours and also other diseases. In particular, molecules which inhibit such kinases are capable of limiting undesired cell proliferations such as those observed in cancers, and can intervene in the prevention, regulation or treatment of neurodegenerative diseases such as Alzheimer's disease or else neuronal apoptosis.

The ALK kinase (or anaplastic lymphoma kinase) is a tyrosine kinase receptor, which belongs to the insulin receptor subfamily. ALK is expressed predominantly in the brain of newborn babies, which suggests a possible role for ALK in brain development.

ALK was initially identified in the form of a constitutively activated, oncogenic fusion protein in large cell anaplastic lymphomas. It has in particular been demonstrated that the mutant protein nucleophosmin (NMP)/ALK has an active tyrosine kinase domain responsible for its oncogenic activity (Falini, B. et al., Blood, 1999, 94, 3509-3515; Morris, S.W. et al., Brit. J. Haematol, 2001 , 1 13, 275-295; Duyster et al.; Kutok & Aster). Recently, fusion proteins of similar forms have been identified in other types of human cancers: DLBCL diffuse large B-cell lymphoma, IMT inflammatory myofibroblastic tumour, ovarian cancer, breast cancer, colorectal cancer, glioblastoma, and also in non-small cell lung carcinomas (NSCLC). NSCLC cancers are common and lethal in human beings. Moreover, ALK gene amplifications and also active mutations have been found in neuroblastomas. In healthy adults, ALK expression is low and remains confined to neuronal tissues. ALK is therefore a therapeutic target in many types of cancers (Cheng and Ott, Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 236-249).

The objective of the present invention is to provide novel ALK kinase-inhibiting compounds intended for cancer treatment.

Thus, the present invention relates to compounds of formula (I):

wherein:

R6 is -CONH2 or a -C(RQ)(Rp)(OH) group in which RQ and Rp are, independently of one another, a hydrogen atom or a (CrC6) alkyl group or together form, with the carbon atom which bears them, a 3- to 5-membered carbocycle;

R is a phenyl or heteroaryl group substituted with R1 , R'1 , R2 and R3;

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, (C C6)alkoxy, (C3-C7)cycloalkyl and aryl, these groups being optionally substituted with one or several substituents selected, independently in each instance, from: amino, hydroxyl, thiol, halogen, (C C6)alkyl, (C C6)alkoxy, (C C6)alkylthio, (C C6)alkylamino, aryloxy, aryl(d-C6)alkoxy, cyano, halo(CrC6)alkyl, carboxyl and carboxy(CrC6)alkyl;

R'1 is a hydrogen atom or a (d-C6)alkoxy group;

R2 is selected from:

- a hydrogen atom, a halogen atom, or a (CrC6)alkyl, (C3-C7)cycloalkyl or (C C6)alkoxy group;

- a heterocycloalkyi, heterocycloalkyl-CH2- or heteroaryl group;

wherein each said heterocycloalkyi, heterocycloalkyl-CH2- and heteroaryl group is optionally substituted with one or several substituents selected, independently in each instance, from: (CrC6)alkyl, (C3-C7)cycloalkyl, (C C6)alkoxy, heterocycloalkyi, carboxy(C C6)alkyl, NR4R5 and OR4;

said (CrC6)alkyl group being optionally substituted with a halogen atom or a (CrC6)alkoxy, heterocycloalkyi, NH2 or OH group; and

R4 and R5 being each, independently of one another, a hydrogen atom, a

(CrC6)alkyl group or a heterocycloalkyi group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;

- an NRaRb group, where Ra and Rb are, independently of one another:

. a hydrogen atom;

. a heterocycloalkyi group, said heterocycloalkyi group being optionally substituted with a (CrC6)alkyl group; or

. a (CrC6)alkyl group, said alkyl group being optionally substituted with an NR4R5 group;

R4 and R5 being each, independently of one another, a hydrogen atom, a (CrC6)alkyl group or a heterocycloalkyi group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;

R3 is a hydrogen atom, a halogen atom or a (CrC6)alkyl group;

wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyi ring fused with the phenyl bearing them, this heterocycloalkyi being optionally substituted with one or several substituents selected, independently in each instance, from: an oxo group and a (CrC6)alkyl group;

R7 is an aryl group or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (d-C6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

n is 1 or 2; and

R8 is a halo(CrC6)alkyl group.

In the compounds of general formula (I), the nitrogen atom(s) can optionally be in oxidized form (N-oxide).

The present invention also relates to com ounds of formula (Γ):

in which:

R is a phenyl or heteroaryl group substituted with R1 , R'1 , R2 and R3;

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, (C C6)alkoxy, (C3-C7)cycloalkyl and aryl, these groups being optionally substituted with one or several substituents selected, independently in each instance, from: amino, hydroxyl, thiol, halogen, (CrC6)alkyl, (CrC6)alkoxy, (CrC6)alkylthio, (CrC6)alkylamino, aryloxy, aryl(C C6)alkoxy, cyano, halo(CrC6)alkyl, carboxyl and carboxy(CrC6)alkyl;

R'1 is a hydrogen atom or a (CrC6)alkoxy group;

R2 is selected from:

- a hydrogen atom, a halogen atom, or a (CrC6)alkyl, (C3-C7)cycloalkyl or (CrC6)alkoxy group;

- a heterocycloalkyl, heterocycloalkyl-CH2- or heteroaryl group;

wherein each said heterocycloalkyl, heterocycloalkyl-CH2- and heteroaryl group is optionally substituted with one or several substituents selected, independently in each instance, from: (d-C6)alkyl, (C3-C7)cycloalkyl, (CrC6)alkoxy, heterocycloalkyl, carboxy(Ci-C6)alkyl, NR4R5 and OR4;

said (CrC6)alkyl group being optionally substituted with a halogen atom or a (C

C6)alkoxy, heterocycloalkyl, NH2 or OH group; and

- an NRaRb group, where Ra and Rb are, independently of one another:

. a hydrogen atom;

. a heterocycloalkyl group, said heterocycloalkyl group being optionally substituted with a (CrC6)alkyl group; or

. a (CrC6)alkyl group, said alkyl group being optionally substituted with an NR4R5 group; R4 and R5 being, independently of one another, a hydrogen atom, a (C-i-C6) alkyl group or a heterocycloalkyl group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;

R3 is a hydrogen atom, a halogen atom or a (C-i-C6)alkyl group;

wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyl ring fused with the phenyl bearing them, this heterocycloalkyl being optionally substituted with one or several substituents selected, independently in each instance, from: an oxo group and a (CrC6)alkyl group;

R7 is an aryl or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (C-i-C6) alkyl or aryl group; said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

n is 1 or 2;

R8 is a halo(CrC6)alkyl group.

The present invention also relates to com ounds of formula ( ):

in which:

Re and Rp are, independently of one another, a hydrogen atom or a (d-C6)alkyl group; or Re and Rp can together form, with the carbon atom bearing them, a 3- to 5-membered carbocycle;

R is a phenyl or heteroaryl group substituted with R1 , R'1 , R2 and R3;

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, (CrC6)alkoxy, (C3-C7)cycloalkyl and aryl, these groups being optionally substituted with one or several substituents selected, independently in each instance, from: amino, hydroxyl, thiol, halogen, (CrC6)alkyl, (CrC6)alkoxy, (CrC6)alkylthio, (CrC6)alkylamino, aryloxy, aryl(CrC6)alkoxy, cyano, halo(CrC6)alkyl, carboxyl and carboxy(CrC6)alkyl;

R'1 represents a hydrogen atom or a (CrC6)alkoxy group;

R2 is selected from:

- a hydrogen atom, a halogen atom, or a (CrC6)alkyl, (C3-C7)cycloalkyl or (CrC6)alkoxy group;

- a heterocycloalkyl, heterocycloalkyl-CH2- or heteroaryl group;

wherein each said heterocycloalkyl, heterocycloalkyl-CH2- and heteroaryl group is optionally substituted with one or several substituents selected, independently in each instance, from: (CrC6)alkyl, (C3-C7)cycloalkyl, (CrC6)alkoxy, heterocycloalkyl, carboxy(Ci-C6)alkyl, NR4R5 and OR4;

said alkyl group being optionally substituted with a halogen atom or a (CrC6)alkoxy, heterocycloalkyl, NH2 or OH group; and

- an NRaRb group, where Ra and Rb are, independently of one another:

. a hydrogen atom;

. a heterocycloalkyl group, said heterocycloalkyl group being optionally substituted with a (CrC6)alkyl group; or

. a (CrC6)alkyl group, said alkyl group being optionally substituted with an NR4R5 group; wherein:

R4 and R5 each is, independently of one another, a hydrogen atom, a (CrC6)alkyl group or a heterocycloalkyl group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;

R3 is a hydrogen atom, a halogen atom or a (CrC6)alkyl group;

wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyl ring fused with the phenyl bearing them, this heterocycloalkyl being optionally substituted with one or several substituents selected, independently in each instance, from: an oxo group and a (d-C6)alkyl group;

R7 is an aryl group or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (CrC6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

n is 1 or 2;

R8 is a halo(CrC6)alkyl group.

Also within the present invention are the precursors (prodrugs) of the compounds of formula (I).

The compounds of formula (I), (Γ) or (I") can comprise one or more asymmetric carbon atoms. They can therefore exist in the form of enantiomers or of diastereoisomers. These enantiomers and diastereoisomers, and also mixtures thereof, including racemic mixtures, form part of the invention.

The compounds of formula (I), (Γ) or (I") can exist in the form of bases or of addition salts with acids. Such addition salts form part of the invention.

The compounds of formula (I), (Γ) or (I") can exist in the form of pharmaceutically acceptable salts.

These salts can be prepared with pharmaceutically acceptable acids, but the salts of other acids that are of use, for example, for purifying or isolating the compounds of formula (I), (Γ) or (I") also form part of the invention.

In the context of the present invention:

- the expression "C,-Cz where t and z can take the values from 1 to 7" means a carbon-based chain which can have from t to z carbon atoms, for example C C3 means a carbon-based chain which can have from 1 to 3 carbon atoms;

- the term "a halogen atom" means: a fluorine, a chlorine, a bromine or an iodine;

- the term "an alkyl group" means: a linear or branched, saturated, hydrocarbon-based aliphatic group comprising, unless otherwise mentioned, from 1 to 12 carbon atoms. By way of examples, mention may be made of methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, tert-butyl or pentyl groups;

- the term "a cycloalkyl group" means: a cyclic carbon-based group comprising, unless otherwise mentioned, from 3 to 6 carbon atoms. By way of examples, mention may be made of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. groups;

- the term "a haloalkyl group" means: an alkyl group as defined above, in which one or more of the hydrogen atoms is (are) replaced with a halogen atom. By way of example, mention may be made of fluoroalkyls, in particular CF3 or CHF2;

- the term "an alkoxy group" means: an -O-alkyl radical where the alkyl group is as previously defined. By way of examples, mention may be made of -0-(CrC4)alkyl groups, and in particular the -O-methyl group, the -O-ethyl group as -0-C3alkyl group, the -O-propyl group, the -O-isopropyl group, and as -0-C4alkyl group, the -O-butyl, -O-isobutyl or -O-tert-butyl group;

- the term "aryl group" means: a cyclic aromatic group comprising between 6 and 10 carbon atoms. By way of examples of aryl groups, mention may be made of phenyl or naphthyl groups;

- the term "a heteroaryl" means: a 5- to 10-membered aromatic monocyclic or bicyclic group containing from 1 to 4 heteroatoms selected from O, S or N. By way of examples, mention may be made of imidazolyl, thiazolyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, oxadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzimidazolyl, indazolyl, benzothiazolyl, isobenzothiazolyl, benzotriazolyl, quinolinyl and isoquinolinyl groups;

by way of a heteroaryl comprising 5 to 6 atoms, including 1 to 4 nitrogen atoms, mention may in particular be made of the following representative groups: pyrrolyl, pyrazolyl, 1 ,2,3-triazolyl, 1 ,2,4-triazolyl, tetrazolyl and 1 ,2,3-triazinyl;

Mention may also be made, by way of heteroaryl, of thiophenyl, oxazolyl, furazanyl, 1 ,2,4-thiadiazolyl, naphthyridinyl, quinoxalinyl, phthalazinyl, imidazo[1 ,2-a]pyridine, imidazo[2,1 -b]thiazolyl, cinnolinyl, benzofurazanyl, azaindolyl, benzimidazolyl, benzothiophenyl, thienopyridyl, thienopyrimidinyl, pyrrolopyridyl, imidazopyridyl, benzoazaindole, 1 ,2,4-triazinyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, purinyl, quinazolinyl, quinolinyl, isoquinolyl, 1 ,3,4-thiadiazolyl, thiazolyl, isothiazolyl, carbazolyl, and also the corresponding groups resulting from their fusion or from fusion with the phenyl nucleus;

- the term "a heterocycloalkyl" means: a 4- to 10-membered, saturated or partially unsaturated, monocyclic or bicyclic group comprising from one to three heteroatoms

selected from O, S or N; the heterocycloalkyi group may be attached to the rest of the molecule via a carbon atom or via a heteroatom; the term bicyclic heterocycloalkyi includes fused bicycles and spiro-type rings.

By way of saturated heterocycloalkyi comprising from 5 to 6 atoms, mention may be made of oxetanyl, tetrahydrofuranyl, dioxolanyl, pyrrolidinyl, azepinyl, oxazepinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl, dithiolanyl, thiazolidinyl, tetrahydropyranyl, tetrahydropyridinyl, dioxanyl, morpholinyl, piperidinyl, piperazinyl, tetrahydrothiopyranyl, dithianyl, thiomorpholinyl or isoxazolidinyl.

Among the heterocycloalkyls, mention may also be made, by way of examples, of bicyclic groups such as (8aR)-hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl, octahydroindozilinyl, diazepanyl, dihydroimidazopyrazinyl and diazabicycloheptanyl groups, or else diazaspiro rings such as 1 ,7-diazaspiro[4.4]non-7-yl or 1 -ethyl-1 ,7-diazaspiro[4.4]non-7-yl.

When the heterocycloalkyi is substituted, the substitution(s) may be on one (or more) carbon atom(s) and/or on the heteroatom(s). When the heterocycloalkyi comprises several substituents, they may be borne by one and the same atom or different atoms.

The abovementioned "alkyl", "cycloalkyl", "aryl", "heteroaryl" and "heterocycloalkyi" radicals can be substituted with one or more substituents. Among these substituents, mention may be made of the following groups: amino, hydroxyl, thiol, oxo, halogen, alkyl, alkoxy, alkylthio, alkylamino, aryloxy, arylalkoxy, cyano, trifluoromethyl, carboxy or carboxyalkyi;

- the term "an alkylthio" means: an -S-alkyl group, the alkyl group being as defined above;

- the term "an alkylamino" means: an -NH-alkyl group, the alkyl group being as defined above;

- the term "an aryloxy" means: an -O-aryl group, the aryl group being as defined above; - the term "an arylalkoxy" means: an aryl-alkoxy- group, the aryl and alkoxy groups being as defined above;

- the term "a carboxyalkyi" means: an HOOC-alkyl- group, the alkyl group being as defined above. As examples of carboxyalkyi groups, mention may in particular be made of carboxymethyl or carboxyethyl;

- the term "a carboxyl" means: a COOH group;

- the term "an oxo" means: "=0".

When an alkyl radical is substituted with an aryl group, the term "arylalkyl" or "aralkyl" radical is used. The "arylalkyl" or "aralkyl" radicals are aryl-alkyl- radicals, the aryl and alkyl groups being as defined above. Among the arylalkyl radicals, mention may in particular be made of the benzyl or phenethyl radicals.

Subgroup 1 is defined by the compounds of formula (I) for which:

R6 is -CONH2 or a -C(RQ)(Rp)(OH) group in which RQ and Rp are, independently of one another, a hydrogen atom or a (d-C6)alkyl group.

Subgroup 2 is defined by the compounds of formula (I) for which:

R6 is -CONH2, -CH2OH or C(CH3)2OH.

Subgroup 3 is defined by the compounds of formula (I) for which:

R is a phenyl, pyridinyl or pyrazolyl group substituted with R1 , R'1 , R2 and R3; R1 , R'1 , R2 and R3 being as defined in formula (I).

Subgroup 4 is defined by the compounds of formula (I) for which:

R is selected from the following groups:

R1 , R'1 , R2 and R3 being as defined in formula (I).

Subgroup 5 is defined by the compounds of formula (I) for which:

R is an (A), (E) or (F) group

R1 , R'1 , R2 and R3 being as defined in formula (I).

Subgroup 6 is defined by the compounds of formula (I) for which:

R is an (A) group

R1 , R'1 , R2 and R3 being as defined in formula (I).

Subgroup 7 is defined by the compounds of formula (I) for which:

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, such as methyl or isopropyl, (CrC6)alkoxy, such as methoxy or isopropyloxy, (C3-C7)cycloalkyl, such as cyclobutyl, and aryl, such as phenyl.

Subgroup 8 is defined by the compounds of formula (I) for which:

R1 is an isopropyloxy group.

Subgroup 9 is defined by the compounds of formula (I) for which:

R'1 is an hydrogen atom or an isopropyloxy group.

Subgroup 10 is defined by the compounds of formula (I) for which:

R'1 is a hydrogen atom.

Subgroup 1 1 is defined by the compounds of formula (I) for which:

R2 is selected from:

- a hydrogen or chlorine atom, or a methyl, cyclopropyl or methoxy group;

- a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1 ,4-diazepan-1 -yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl, 1 ,7-diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group;

these groups being optionally substituted with one or more substituents selected, independently in each instance, from: (d-C6)alkyl, (C3-C7)cycloalkyl, (CrC6)alkoxy, heterocycloalkyl, carboxy(CrC6)alkyl, NR4R5 and OR4;

said (CrC6)alkyl group being optionally substituted with a halogen atom or a (C

C6)alkoxy, heterocycloalkyl, NH2 or OH group; and

R4 and R5 each is, independently of one another, a hydrogen atom, a (d-C6)alkyl group, such as methyl or ethyl, or a heterocycloalkyl group, such as oxetanyl; or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to

7-membered ring, such as pyrrolidinyl;

- an NRaRb group, where Ra and Rb are, independently of one another:

. a hydrogen atom;

. a piperidinyl group or tetrahydropyranyl group, wherein each of said piperidinyl and tetrahydropyranyl groups is independently optionally substituted with a (C-i-C6)alkyl group, such as methyl; or

. a methyl or ethyl group, said group being optionally substituted with an NR4R5 group; wherein:

R4 and R5 each is, independently of one another, a hydrogen atom, a (C-i-C6)alkyl group, such as methyl or ethyl, or a heterocycloalkyl group, such as oxetanyl; or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to

7-membered ring, such as pyrrolidinyl;

R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (C-i-C6)alkyl group, such as a methyl;

and when R corresponds to formula (A), R2 and R3 can together form an azepinyl or oxazepinyl ring fused with the phenyl bearing them, this azepinyl or oxazepinyl being optionally substituted with one or more substituents selected, independently in each instance, from: an oxo group and a (CrC6)alkyl group, such as methyl.

Subgroup 12 is defined by the compounds of formula (I) for which:

R2 is a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1 ,4-diazepan-1 -yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl, 1 ,7-diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group;

these groups being optionally substituted with at least one substituent selected from: (C C6)alkyl, such as methyl, ethyl or isopropyl, (C3-C7)cycloalkyl, such as cyclopropyl, (C C6)alkoxy, such as methoxy, heterocycloalkyl, such as oxetanyl or pyrrolidinyl, carboxy(C C6)alkyl, such as C(0)0(CH3)3, NR4R5 and OH;

said alkyl group being optionally substituted with a (C-i-C6)alkoxy group, such as methoxy, or OH;

R4 and R5 being, independently of one another, a hydrogen atom, a (C-i-C6)alkyl group, such as methyl or ethyl, or a heterocycloalkyl group, such as oxetanyl;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring, such as pyrrolidinyl;

R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (d-C6)alkyl group, such as a methyl.

Subgroup 13 is defined by the compounds of formula (I) for which:

R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with at least one substituent selected from: (CrC6)alkyl, (C3-C7)cycloalkyl, (CrC-6)alkoxy, heterocycloalkyl, carboxy(Ci-C6)alkyl, NR4R5 and OR4;

said alkyl group being optionally substituted with a halogen atom or a (C-i-C6)alkoxy, heterocycloalkyl, NH2 or OH group;

R4 and R5 being as defined in formula (I);

R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (C-i-C6)alkyl group, such as a methyl.

Subgroup 14 is defined by the compounds of formula (I) for which:

R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with at least one substituent selected from: a methyl, ethyl, isopropyl, cyclopropyl, OH, oxetanyl, pyrrolidinyl, C(0)0(CH3)3, NR4R5 and OR4 group;

said methyl, ethyl and isopropyl groups being optionally substituted with a (CrC6)alkoxy group, such as methoxy, or with an OH;

R4 and R5 being, independently of one another, a hydrogen atom, a (CrC6)alkyl group, such as methyl, or a heterocycloalkyl group, such as oxetanyl;

R3 is a hydrogen or fluorine atom or a methyl.

Subgroup 15 is defined by the compounds of formula (I) for which:

R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with at least one substituent selected from: a methyl, ethyl or isopropyl group:

R3 is a hydrogen or fluorine atom or a methyl.

Subgroup 16 is defined by the compounds of formula (I) for which:

R2 is a group selected from the following groups:

R3 is a hydrogen or fluorine atom or a methyl.

Subgroup 17 is defined by the compounds of formula (I) for which:

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (C-i-C6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

n is 1 or 2;

R8 is a halo(CrC6)alkyl group.

Subgroup 18 is defined by the compounds of formula (I) for which:

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents independently selected from:

cyano, halogen, such as chlorine or fluorine, (d-C6)alkyl, such as methyl, OR'4, CH2OH, CH2NH2, S(0)nR'4 and OR8;

wherein:

R'4 is a (CrC6)alkyl group, such as methyl or ethyl;

n is 1 ;

R8 is a halo(CrC6)alkyl group, such as CF3 or CHF2.

Subgroup 19 is defined by the compounds of formula (I) for which R, R6 and R7 are defined in one of subgroups 1 to 18 above.

Subgroup 20 is defined by the compounds of formula (I) for which:

R6 is -CONH2 or a -C(Ra)(Rp)(OH) group in which Ra and Rp are, independently of one another, a hydrogen atom or a (CrC6)alkyl group;

R is a phenyl, pyridinyl or pyrazolyl group substituted with R1 , R'1 , R2 and R3;

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, such as methyl or isopropyl, (CrC6)alkoxy, such as methoxy or isopropyloxy, (C3-C7)cycloalkyl, such as cyclobutyl, and aryl, such as phenyl;

R'1 is a hydrogen atom or an isopropyloxy group;

R2 is selected from:

- a hydrogen or chlorine atom or a methyl, cyclopropyl or methoxy group;

- a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1 ,4-diazepan-1 -yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl, 1 ,7-diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group;

these groups being optionally substituted with one or more substituents independently selected from: (CrC6)alkyl, (C3-C7)cycloalkyl, (CrC6)alkoxy, heterocycloalkyl, carboxy(C C6)alkyl, NR4R5 and OR4;

said alkyl group being optionally substituted with a halogen atom or a (C

C6)alkoxy, heterocycloalkyl, NH2 or OH group; and

- an NRaRb group, where Ra and Rb are, independently of one another:

. a hydrogen atom;

. a piperidinyl or tetrahydropyranyl group, said group being optionally substituted with a (CrC6)alkyl group, such as methyl; or

. a methyl or ethyl group, said group being optionally substituted with an NR4R5 group; R4 and R5 being, independently of one another, a hydrogen atom, a (d-C6)alkyl group, such as methyl or ethyl, or a heterocycloalkyl group, such as oxetanyl;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring, such as a pyrrolidinyl;

R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrC6)alkyl group, such as a methyl;

wherein when R corresponds to formula (A), R2 and R3 may together form an azepinyl or oxazepinyl ring fused with the phenyl bearing them, this azepinyl or oxazepinyl ring being optionally substituted with at least one substituent selected from: an oxo group and a (C C6)alkyl group;

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (CrC6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

n is 1 or 2; and

R8 is a halo(CrC6)alkyl group.

Subgroup 21 is defined by the compounds of formula (I) for which:

R6 is -CONH2 or a -C(RQ)(Rp)(OH) group in which RQ and Rp are, independently of one another, a hydrogen atom or a (CrC6)alkyl group;

R is selected from the following groups:

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, such as methyl or isopropyl, (CrC6)alkoxy, such as methoxy or isopropyloxy, (C3-C7)cycloalkyl, such as cyclobutyl, and aryl, such as phenyl;

R'1 is a hydrogen atom or an isopropyloxy group;

R2 is a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1 ,4-diazepan-1 -yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl, 1 ,7-diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group;

these groups being optionally substituted with one or more substituents selected, independently in each instance, from: (d-C6)alkyl, such as methyl, ethyl or isopropyl, (C3-C7)cycloalkyl, such as cyclopropyl, (C-i-C6)alkoxy, such as methoxy, heterocycloalkyi, such as oxetanyl or pyrrolidinyl, carboxy(C-i-C6)alkyl, such as C(0)0(CH3)3, NR4R5 and OH; said (CrC6)alkyl group being optionally substituted with a (C-i-C6)alkoxy group, such as methoxy, or OH;

wherein:

R4 and R5 each is, independently of one another, a hydrogen atom, a (C C6)alkyl group or a heterocycloalkyi group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;

R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrC6)alkyl group, such as a methyl;

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (C-i-C6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

n 1 or 2; and

R8 is a halo(CrC6)alkyl group.

Subgroup 22 is defined by the compounds of formula (I) for which:

R6 is -CONH2 or a -C(RQ)(Rp)(OH) group in which RQ and Rp are, independently of one another, a hydrogen atom or a (C-i-C6)alkyl group;

is an (A), (E) or (F) group

R1 is an isopropyloxy group;

R'1 is a hydrogen atom;

R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with one or more substituents selected, independently in each instance, from: a methyl, ethyl, isopropyl, cyclopropyl, OH, oxetanyl, pyrrolidinyl, C(0)0(CH3)3, NR4R5 and OR4 group; said methyl, ethyl and isopropyl groups being optionally substituted with a (C-i-C6)alkoxy group, such as methoxy, or with an OH;

wherein R4 and R5 each is, independently of one another, a hydrogen atom, a (C C6)alkyl group, such as methyl, or a heterocycloalkyl group, such as oxetanyl;

R3 is a hydrogen or fluorine atom or a methyl;

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, such as chlorine or fluorine, (CrC6)alkyl, such as methyl, OR'4, CH2OH, CH2NH2, S(0)nR'4 and OR8;

wherein:

R'4 is a (CrC6)alkyl group, such as methyl or ethyl;

n is 1 ; and

R8 is a halo(CrC6)alkyl group, such as CF3 or CHF2.

Subgroup 23 is defined by the compounds of formula (Γ) for which:

R is a phenyl, pyridinyl or pyrazolyl group substituted with R1 , R'1 , R2 and R3; R1 , R'1 ,

R2 and R3 being as defined in formula (Γ).

Subgroup 24 is defined by the compounds of formula (Γ) for which:

R is selected from the following groups:

R1 , R'1 , R2 and R3 being as defined in formula (Γ).

Subgroup 25 is defined by the compounds of formula (Γ) for which:

R is an (A (E) or (F) group

R1 , R'1 , R2 and R3 being as defined in formula (Γ).

Subgroup 26 is defined by the compounds of formula (Γ) for which:

R is an (A) group

R1 , R'1 , R2 and R3 being as defined in formula (Γ).

Subgroup 27 is defined by the compounds of formula (Γ) for which:

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, such as methyl or isopropyl, (CrC6)alkoxy, such as methoxy or isopropyloxy, (C3-C7)cycloalkyl, such as cyclobutyl, and aryl, such as phenyl.

Subgroup 28 is defined by the compounds of formula (Γ) for which:

R1 is an isopropyloxy group.

Subgroup 29 is defined by the compounds of formula (Γ) for which:

R'1 is a hydrogen atom or an isopropyloxy group.

Subgroup 30 is defined by the compounds of formula (Γ) for which:

R'1 is a hydrogen atom.

Subgroup 31 is defined by the compounds of formula (Γ) for which:

R2 is selected from:

- a hydrogen atom or a methyl, cyclopropyl or methoxy group;

- a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1 ,4-diazepan-1 -yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl, 1 ,7-diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group;

these groups being optionally substituted with one or several substituents independently selected from: (d-C6)alkyl, (C3-C7)cycloalkyl, (CrC6)alkoxy, heterocycloalkyl, carboxy(C C6)alkyl, NR4R5 and OR4;

said alkyl group being optionally substituted with a halogen atom or a (CrC6)alkoxy, heterocycloalkyl, NH2 or OH group; and

- an NRaRb group, where Ra and Rb are, independently of one another:

. a hydrogen atom;

. a piperidinyl or tetrahydropyranyl group, said group being optionally substituted with a (CrC6)alkyl group, such as methyl; or

. a methyl or ethyl group, said alkyl group being optionally substituted with an NR4R5 group;

R4 and R5 being, independently of one another, a hydrogen atom, a (CrC6)alkyl group, such as methyl or ethyl, or a heterocycloalkyl group, such as oxetanyl;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring, such as a pyrrolidinyl;

R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrC6)alkyl group, such as a methyl;

and when R corresponds to formula (A), R2 and R3 can together form an azepinyl or oxazepinyl ring, fused with the phenyl bearing them, this azepinyl or oxazepinyl ring being optionally substituted with at least one substituent selected from: an oxo group and a (C C6)alkyl group, such as methyl.

Subgroup 32 is defined by the compounds of formula (Γ) for which:

R2 is a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1 ,4-diazepan-1 -yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl, 1 ,7- diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group;

these groups being optionally substituted with one or several substituents independently selected from: (CrC6)alkyl, such as methyl, ethyl or isopropyl, (C3-C7)cycloalkyl, such as cyclopropyl, (d-C6)alkoxy, such as methoxy, heterocycloalkyl, such as oxetanyl or pyrrolidinyl, carboxy(C C6)alkyl, such as C(0)0(CH3)3, NR4R5 and OH;

said alkyl group being optionally substituted with a (CrC6)alkoxy group, such as methoxy, or OH;

R4 and R5 being, independently of one another, a hydrogen atom, a (C-i-C6) alkyl group, such as methyl or ethyl, or a heterocycloalkyl group, such as oxetanyl;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring, such as a pyrrolidinyl;

R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (C-i-C6)alkyl group, such as a methyl.

Subgroup 33 is defined by the compounds of formula (Γ) for which:

R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with one or several substituents independently selected from: (CrC6)alkyl, (C3-C7)cycloalkyl, (C

C6)alkoxy, heterocycloalkyl, carboxy(CrC-6) alkyl, NR4R5 and OR4;

said alkyl group being optionally substituted with a halogen atom or a (CrC6)alkoxy, heterocycloalkyl, NH2 or OH group;

R4 and R5 being as defined in formula (I);

R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrC6)alkyl group, such as a methyl.

Subgroup 34 is defined by the compounds of formula (Γ) for which:

R2 represents a piperidinyl or piperazinyl group, these groups being optionally substituted with one or several substituents independently selected from: a methyl, ethyl, isopropyl, cyclopropyl, OH, oxetanyl, pyrrolidinyl, C(0)0(CH3)3, NR4R5 and OR4 group;

said alkyl group being optionally substituted with a (C-i-C6)alkoxy group, such as methoxy, or with an OH;

R4 and R5 being, independently of one another, a hydrogen atom, a (C-i-C6) alkyl group, such as methyl, or a heterocycloalkyl group, such as oxetanyl;

R3 is a hydrogen or fluorine atom or a methyl.

Subgroup 35 is defined by the compounds of formula (Γ) for which:

R2 is a piperidinyl group or piperazinyl group, these piperidinyl or piperazinyl groups being optionally substituted with one or more substituents selected, independently in each instance, from: a methyl, ethyl or isopropyl group;

R3 is a hydrogen or fluorine atom or a methyl.

Subgroup 36 is defined by the compounds of formula (Γ) for which:

R2 is a group selected from the following groups:

R3 is a hydrogen or fluorine atom or a methyl.

Subgroup 37 is defined by the compounds of formula (Γ) for which:

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (CrC6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

n is 1 or 2; and

R8 is a halo(CrC6)alkyl group.

Subgroup 38 is defined by the compounds of formula (Γ) for which:

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, such as chlorine or fluorine, (d-C6)alkyl, such as methyl, OR'4, CH2OH, CH2NH2, S(0)nR'4 and OR8;

wherein:

R'4 is a (CrC6)alkyl group, such as methyl or ethyl;

n is 1 ;

R8 is a halo(CrC6)alkyl group, such as CF3 or CHF2.

Subgroup 39 is defined by the compounds of formula (Γ) for which R and R7 are defined in one of subgroups 23 to 38 above.

Subgroup 40 is defined by the compounds of formula (Γ) for which:

R is a phenyl, pyridinyl or pyrazolyl group substituted with R1 , R'1 , R2 and R3;

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, such as methyl or isopropyl, (CrC6)alkoxy, such as methoxy or isopropyloxy, (C3-C7)cycloalkyl, such as cyclobutyl, and aryl, such as phenyl;

R'1 is a hydrogen atom or an isopropyloxy group;

R2 is selected from:

- a hydrogen atom or a methyl, cyclopropyl or methoxy group;

- a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1 ,4-diazepan-1 -yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl, 1 ,7-diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group;

these groups being optionally substituted with one or more substituents selected, independently in each instance, from: (CrC6)alkyl, (C3-C7)cycloalkyl, (CrC6)alkoxy, heterocycloalkyl, carboxy(CrC6)alkyl, NR4R5 and OR4;

said alkyl group being optionally substituted with a halogen atom or a (CrC6)alkoxy, heterocycloalkyl, NH2 or OH group; and

- an NRaRb group, where Ra and Rb are, independently of one another:

. a hydrogen atom;

. a piperidinyl or tetrahydropyranyl group, said group being optionally substituted with a (CrC6)alkyl group, such as methyl; or

. a methyl or ethyl group, said alkyl group being optionally substituted with an NR4R5 group;

R4 and R5 are, independently of one another, a hydrogen atom, a (d-C6)alkyl group, such as methyl or ethyl, or a heterocycloalkyi group, such as oxetanyl;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring, such as a pyrrolidinyl;

R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrC6)alkyl group, such as a methyl;

and when R corresponds to formula (A), R2 and R3 can together form an azepinyl or oxazepinyl ring, fused with the phenyl bearing them, this heterocycloalkyi being optionally substituted with at least one substituent selected from: an oxo group and a (CrC6)alkyl group, such as methyl;

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (CrC6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

n is 1 or 2; and

R8 is a halo(CrC6)alkyl group.

Subgroup 41 is defined by the compounds of formula (Γ) for which:

R is selected from the following groups:

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, such as methyl or isopropyl, (CrC6)alkoxy, such as methoxy or isopropyloxy, (C3-C7)cycloalkyl, such as cyclobutyl, and aryl, such as phenyl;

R'1 is a hydrogen atom or an isopropyloxy group;

R2 is a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1 ,4-diazepan-1 -yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl, 1 ,7-diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group;

these groups being optionally substituted with one or more substituents selected, independently in each instance, from: (d-C6)alkyl, such as methyl, ethyl or isopropyl, (C3-C7)cycloalkyl, such as cyclopropyl, (C-i-C6)alkoxy, such as methoxy, heterocycloalkyi, such as oxetanyl or pyrrolidinyl, carboxy(C-i-C6)alkyl, such as C(0)0(CH3)3, NR4R5 and OH; said alkyl group being optionally substituted with a (C-i-C6)alkoxy group, such as methoxy, or OH;

R4 and R5 being, independently of one another, a hydrogen atom, a (C-i-C6) alkyl group, such as methyl or ethyl, or a heterocycloalkyi group, such as oxetanyl;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring, such as a pyrrolidinyl;

R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrC6)alkyl group, such as a methyl;

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (C-i-C6) alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

n is 1 or 2;

R8 is a halo(CrC6)alkyl group.

Subgroup 42 is defined by the compounds of formula (Γ) for which:

R is an (A), (E) or (F) group

R1 is an isopropyloxy group;

R'1 is a hydrogen atom;

R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with one or more substituents selected, independently in each instance, from: a methyl, ethyl, isopropyl, cyclopropyl, OH, oxetanyl, pyrrolidinyl, C(0)0(CH3)3, NR4R5 and OR4 group; said alkyl group being optionally substituted with a (d-C6)alkoxy group, such as methoxy, or with an OH;

R4 and R5 being, independently of one another, a hydrogen atom, a (C-i-C6)alkyl group, such as methyl, or a heterocycloalkyl group, such as oxetanyl;

R3 is a hydrogen or fluorine atom or a methyl;

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, such as chlorine or fluorine, (CrC6)alkyl, such as methyl, OR'4, CH2OH, CH2NH2, S(0)nR'4 and OR8;

wherein:

R'4 is a (CrC6)alkyl group, such as methyl or ethyl;

n is 1 ;

R8 is a halo(CrC6)alkyl group, such as CF3 or CHF2.

Subgroup 43 is defined by the compounds of formula (I") for which:

R is a phenyl, pyridinyl or pyrazolyl group substituted with R1 , R'1 , R2 and R3; R1 , R'1 ,

R2 and R3 being as defined in formula (I").

Subgroup 44 is defined by the compounds of formula (I") for which:

R is selected from the following groups:

R1 , R'1 , R2 and R3 being as defined in formula (I").

Subgroup 45 is defined by the compounds of formula (I") for which:

R is a an (A) group

R1 , R'1 , R2 and R3 being as defined in formula (I").

Subgroup 46 is defined by the compounds of formula (I") for which:

R1 is selected from the following groups: (CrC6)alkyl, such as isopropyl, and (CrC6)alkoxy, such as methoxy or isopropyloxy.

Subgroup 47 is defined by the compounds of formula (I") for which:

R1 is an isopropyloxy group.

Subgroup 48 is defined by the compounds of formula (I") for which:

R'1 is a hydrogen atom.

Subgroup 49 is defined by the compounds of formula (I") for which:

R2 is selected from:

- a hydrogen or chlorine atom or a methyl group;

- a pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, 1 ,7-diazaspiro[4.4]non-7-yl or pyrazolyl group;

these groups being optionally substituted with at least one (d-C6)alkyl group;

R3 is a hydrogen atom or a (CrC6)alkyl group, such as a methyl.

Subgroup 50 is defined by the compounds of formula (I") for which:

R2 is selected from a pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, 1 ,7- diazaspiro[4.4]non-7-yl or pyrazolyl group;

these groups being optionally substituted with at least one (CrC6)alkyl group, such as methyl;

R3 is a hydrogen atom or a (CrC6)alkyl group, such as a methyl.

Subgroup 51 is defined by the compounds of formula (I") for which:

R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with at least one (d-C6)alkyl group, such as methyl;

R3 is a hydrogen atom or a (CrC6)alkyl group, such as a methyl.

Subgroup 52 is defined by the compounds of formula (I") for which:

R2 is a group selected from the following groups:

R3 is a hydrogen atom or a methyl.

Subgroup 53 is defined by the compounds of formula (I") for which:

R7 is a phenyl or pyridinyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (CrC6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (CrC6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a hydrogen atom or an NH2 or OH group;

n is 1 or 2;

R8 is a halo(CrC6)alkyl group.

Subgroup 54 is defined by the compounds of formula (I") for which:

R7 is a phenyl or pyridinyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: halogen, such as fluorine, (C C6)alkyl, such as methyl, OR'4 and OR8;

wherein:

R'4 is a (CrC6)alkyl group, such as methyl or ethyl;

R8 is a halo(CrC6)alkyl group, such as CF3.

Subgroup 55 is defined by the compounds of formula (I") for which R and R7 are defined in one of subgroups 43 to 54 above.

Subgroup 56 is defined by the compounds of formula (I") for which:

R is a phenyl, pyridinyl or pyrazolyl group substituted with R1 , R'1 , R2 and R3;

R1 is selected from the following groups: (CrC6)alkyl, such as isopropyl, (CrC6)alkoxy, such as methoxy or isopropyloxy;

R'1 is a hydrogen atom;

R2 is selected from:

- a hydrogen or chlorine atom or a methyl group;

- a pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, 1 ,7-diazaspiro[4.4]non-7-yl or pyrazolyl group;

these groups being optionally substituted with at least one (CrC6)alkyl group;

R3 is a hydrogen atom or a (C-i-C6)alkyl group, such as a methyl;

R7 is a phenyl or pyridinyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (d-C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

CLAIMS

1. A compound of formula (I):

wherein:

R6 is -CONH2 or a -C(Ra)(Rp)(OH) group in which Ra and Rp are, independently of one another, a hydrogen atom or a (CrC6) alkyl group or together form, with the carbon atom which bears them, a 3- to 5-membered carbocycle;

R is a phenyl or heteroaryl group substituted with R1 , R'1 , R2 and R3;

R1 is a hydrogen atom or is selected from the following groups: (d-C6)alkyl, (C C6)alkoxy, (C3-C7)cycloalkyl and aryl, these groups being optionally substituted with one or several substituents selected, independently in each instance, from: amino, hydroxyl, thiol, halogen, (CrC6)alkyl, (CrC6)alkoxy, (CrC6)alkylthio, (C C6)alkylamino, aryloxy, aryl(CrC6)alkoxy, cyano, halo(CrC6)alkyl, carboxyl and carboxy(CrC6)alkyl;

R'1 is a hydrogen atom or a (CrC6)alkoxy group;

R2 is selected from:

- a hydrogen atom, a halogen atom, or a (CrC6)alkyl, (C3-C7)cycloalkyl or (C C6)alkoxy group;

- a heterocycloalkyl, heterocycloalkyl-CH2- or heteroaryl group;

wherein each said heterocycloalkyl, heterocycloalkyl-CH2- and heteroaryl group is optionally substituted with one or several substituents selected, independently in each instance, from: (CrC6)alkyl, (C3-C7)cycloalkyl, (CrC6)alkoxy, heterocycloalkyl, carboxy(CrC6)alkyl, NR4R5 and OR4;

said (CrC6)alkyl group being optionally substituted with a halogen atom or a (CrC6)alkoxy, heterocycloalkyl, NH2 or OH group; and

R4 and R5 being each, independently of one another, a hydrogen atom, a

(CrC6)alkyl group or a heterocycloalkyl group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;

- an NRaRb group, where Ra and Rb are, independently of one another:

. a hydrogen atom;

. a heterocycloalkyl group, said heterocycloalkyl group being optionally substituted with a (CrC6)alkyl group; or

. a (CrC6)alkyl group, said alkyl group being optionally substituted with an NR4R5 group;

R4 and R5 being each, independently of one another, a hydrogen atom, a (CrC6)alkyl group or a heterocycloalkyl group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;

R3 is a hydrogen atom, a halogen atom or a (d-C6)alkyl group;

wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyl ring fused with the phenyl bearing them, this heterocycloalkyl being optionally substituted with one or several substituents selected, independently in each instance, from: an oxo group and a (CrC6)alkyl group;

R7 is an aryl group or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (C-i-C6) alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

n is 1 or 2; and

R8 is a halo(CrC6)alkyl group;

wherein each of the nitrogen atom(s) of the compounds of formula (I) may be, independently of one another, optionally in oxidized form (N-oxide);

or a pharmaceutically acceptable salt thereof.

2. A compound according to Claim 1 , wherein:

R6 is -CONH2 or a -C(RQ)(Rp)(OH) group wherein RQ and Rp are, independently of one another, a hydrogen atom or a (d-C6)alkyl group;

or a pharmaceutically acceptable salt thereof.

3. A compound according to Claim 1 or 2, wherein:

R is a phenyl, pyridinyl or pyrazolyl group substituted with R1 , R'1 , R2 and R3;

R1 , R'1 , R2 and R3 being as defined in formula (I) according to Claim 1 ;

or a pharmaceutically acceptable salt thereof.

4. A compound according to any one of Claims 1 to 3, wherein R is selected from the following groups:

R1 , R'1 , R2 and R3 being as defined in formula (I) according to Claim 1 ;

or a pharmaceutically acceptable salt thereof.

5. A compound according to any one of Claims 1 to 4, wherein R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, (CrC6)alkoxy, (C3-C7)cycloalkyl and aryl;

or a pharmaceutically acceptable salt thereof.

6. A compound of formula (I) according to any one of Claims 1 to 5, wherein R'1 is a hydrogen atom or an isopropyloxy group;

or a pharmaceutically acceptable salt thereof.

7. A compound according to any one of Claims 1 to 6, wherein:

R2 is selected from:

- a hydrogen or chlorine atom or a methyl, cyclopropyl or methoxy group;

- a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1 ,4-diazepan-1 -yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1 ,2-a]pyrazin- 2(1 H)-yl, 1 ,7-diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group; these groups being optionally substituted with one or more substituents selected, independently in each instance, from: (d-C6)alkyl, (C3-C7)cycloalkyl, (C C6)alkoxy, heterocycloalkyl, carboxy(CrC6)alkyl, NR4R5 and OR4;

said (CrC6)alkyl group being optionally substituted with a halogen atom or a (CrC6)alkoxy, heterocycloalkyl, NH2 or OH group;

wherein:

R4 and R5 each is, independently of one another, a hydrogen atom, a (C C6)alkyl group or a heterocycloalkyl group;

or else R4 and R5 together form, with the nitrogen atom bearing them, a 4- to 7-membered ring; and

- an NRaRb group, where Ra and Rb are, independently of one another:

. a hydrogen atom;

. a piperidinyl group or tetrahydropyranyl group, wherein each of said piperidinyl and tetrahydropyranyl groups is independently optionally substituted with a (C C6)alkyl group; or

. a methyl or ethyl group, said alkyl group being optionally substituted with an NR4R5 group;

wherein:

R4 and R5 each is, independently of one another, a hydrogen atom, a (C C6)alkyl group or a heterocycloalkyl group;

or else R4 and R5 together form, with the nitrogen atom bearing them, a 4- to 7-membered ring; and

R3 is a hydrogen atom, a halogen atom or a (CrC6)alkyl group;

wherein when R corresponds to formula (A), R2 and R3 can together form an azepinyl or oxazepinyl ring fused with the phenyl bearing them, this azepinyl or oxazepinyl being optionally substituted with one or more substituents selected, independently in each instance, from: an oxo group and a (d-C6)alkyl group;

or a pharmaceutically acceptable salt thereof.

8. A compound according to any one of Claims 1 to 7, wherein:

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

- R'4 is a hydrogen atom or a (CrC6)alkyl group or aryl group, said (CrC6)alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

- n is 1 or 2;

- R8 is a halo(CrC6)alkyl group;

or a pharmaceutically acceptable salt thereof.

9. A compound according to any one of Claims 1 to 8, wherein

R6 is -CONH2 or a -C(RQ)(Rp)(OH) group wherein RQ and Rp are, independently of one another, a hydrogen atom or a (CrC6)alkyl group;

R is a phenyl, pyridinyl or pyrazolyl group substituted with R1 , R'1 , R2 and R3;

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, (CrC6)alkoxy, (C3-C7)cycloalkyl and aryl;

R'1 is a hydrogen atom or an isopropyloxy group;

R2 is selected from:

- a hydrogen or chlorine atom or a methyl, cyclopropyl or methoxy group;

- a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1 ,4- diazepan-1 -yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)- yl, 1 ,7-diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group; these groups being optionally substituted with one or more substituents independently selected from: (d-C6)alkyl, (C3-C7)cycloalkyl, (CrC6)alkoxy, heterocycloalkyl, carboxy(C C6)alkyl, NR4R5 and OR4;

said (CrC6)alkyl group being optionally substituted with a halogen atom or a

(CrC6)alkoxy, heterocycloalkyl, NH2 or OH group;

and wherein:

R4 and R5 each is, independently of one another, a hydrogen atom, a (C C6)alkyl group or a heterocycloalkyl group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; and

- an NRaRb group, where Ra and Rb are, independently of one another:

. a hydrogen atom;

. a piperidinyl or tetrahydropyranyl group, said group being optionally substituted with a (CrC6)alkyl group; or

. a methyl or ethyl group, said group being optionally substituted with an NR4R5 group;

wherein:

R4 and R5 each is, independently of one another, a hydrogen atom, a (C C6)alkyl group or a heterocycloalkyl group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; and

R3 is a hydrogen atom, a halogen atom or a (CrC6)alkyl group;

wherein when R corresponds to formula (A), R2 and R3 may together form an azepinyl or oxazepinyl ring fused with the phenyl bearing them, this azepinyl or oxazepinyl ring being optionally substituted with at least one substituent selected from: an oxo group and a (CrC6)alkyl group;

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each

instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

. R'4 is a hydrogen atom or a (d-C6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

. n is 1 or 2; and

. R8 is a halo(CrC6)alkyl group;

or a pharmaceutically acceptable salt thereof.

10. A compound according to any one of Claims 1 to 9, wherein:

R6 is -CONH2 or a -C(Ra)(Rp)(OH) group wherein Ra and Rp are, independently of one another, a hydrogen atom or a (CrC6)alkyl group;

R is selected from the following groups:

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, (CrC6)alkoxy, (C3-C7)cycloalkyl and aryl;

R'1 is a hydrogen atom or an isopropyloxy group;

R2 is a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1 ,4-diazepan-1 -yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl, 1 ,7-diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group; these groups being optionally substituted with one or more substituents selected, independently in each instance, from: (d-C6)alkyl, (C3-C7)cycloalkyl, (CrC6)alkoxy, heterocycloalkyl, carboxy(Ci-C6)alkyl, NR4R5 and OH;

said (CrC6)alkyl group being optionally substituted with a (CrC6)alkoxy group or

OH;

wherein:

R4 and R5 each is, independently of one another, a hydrogen atom, a (C C6)alkyl group or a heterocycloalkyl group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;

R3 is a hydrogen atom, a halogen atom or a (C-i-C6)alkyl group;

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (CrC6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

n is 1 or 2; and

R8 is a halo(CrC6)alkyl group;

or a pharmaceutically acceptable salt thereof.

11. A compound according to any one of Claims 1 to 10, wherein:

R6 is -CONH2 or a -C(RQ)(Rp)(OH) group wherein RQ and Rp are, independently of one another, a hydrogen atom or a (C-i-C6)alkyl group;

R is an (A), (E) or (F) group

R1 is an isopropyloxy group;

R'1 is a hydrogen atom;

R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with one or more substituents selected, independently in each instance, from: a methyl, ethyl, isopropyl, cyclopropyl, OH, oxetanyl, pyrrolidinyl, C(0)0(CH3)3, NR4R5 and OR4 group;

said methyl, ethyl and isopropyl groups being optionally substituted with a (C C6)alkoxy group, such as methoxy, or with an OH;

wherein R4 and R5 each is, independently of one another, a hydrogen atom, a (CrC6)alkyl group or a heterocycloalkyl group;

R3 is a hydrogen or fluorine atom or a methyl;

R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4 and OR8;

wherein:

R'4 is a (CrC6)alkyl group;

n is equal to 1 ; and

R8 is a halo(CrC6)alkyl group;

or a pharmaceutically acceptable salt thereof.

12. A compound according to any one of Claims 1 to 1 1 , wherein it is selected from the following compounds:

2-({2-methoxy-4-[4-(pyrrolidin-1 -yl)piperidin-1 -yl]phenyl}amino)-7-phenylthieno-[3,2-d]pyrimidine-6-carboxamide;

2-({2-methyl-4-[4-(pyrrolidin-1 -yl)piperidin-1 -yl]phenyl}amino)-7-phenylthieno-[3,2-d]pyrimidine-6-carboxamide;

7-(3-chlorophenyl)-2-({2-methoxy-4-[4-(pyrrolidin-1 -yl)piperidin-1 -yl]phenyl}-amino)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(4-chlorophenyl)-2-({2-methoxy-4-[4-(pyrrolidin-1 -yl)piperidin-1 -yl]phenyl}-amino)thieno[3,2-d]pyrimidine-6-carboxamide;

2-({2-methoxy-4-[4-(pyrrolidin-1 -yl)piperidin-1 -yl]phenyl}amino)-7-(thiophen-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-({2-methoxy-4-[4-(pyrrolidin-1 -yl)piperidin-1 -yl]phenyl}amino)-7-(thiophen-2-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-({2-methoxy-4-[4-(propan-2-yl)piperazin-1 -yl]phenyl}amino)-7-phenylthieno-[3,2-d]pyrimidine-6-carboxamide;

2-({2-methoxy-4-[1 -(propan-2-yl)piperidin-4-yl]phenyl}amino)-7-phenylthieno-[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(4-fluoro-3-methoxyphenyl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(4-methoxyphenyl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(4-fluorophenyl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[2-methoxy-5-methyl-4-(1 -methylpiperidin-4-yl)phenyl]amino}-7-phenylthieno[3,2 d]pyrimidine-6-carboxamide;

7-(4-fluoro-2-methoxyphenyl)-2-{[2-methoxy-4-(4-methylpiperazin-1 -yl)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[2-methoxy-4-(4-methylpiperazin-1 -yl)phenyl]amino}-7-(3-methoxyphenyl)-thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[5-methyl-4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide;

2-{[2-methoxy-5-methyl-4-(1 -methylpiperidin-3-yl)phenyl]amino}-7-phenylthieno[3,2 d]pyrimidine-6-carboxamide;

2-({2-methoxy-4-[1 -(propan-2-yl)piperidin-4-yl]phenyl}amino)-7-phenylthieno-[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1 -methyl-1 H-pyrazol-5-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-ethoxyphenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(3-methoxyphenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[5-methyl-4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(pyridin-2-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(4-methyl-1 ,4-diazepan-1 -yl)-2-(propan-2-yloxy)phenyl]amino}-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-fluoro-5-methoxyphenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(3-cyanophenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-[2- (trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-phenylthieno- [3,2-d]pyrimidine-6-carboxamide;

2-({4-[(1 S,4S)-5-methyl-2,5-diazabicyclo[2.2.1 ]hept-2-yl]-2-(propan-2-yloxy)-phenyl}amino)-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1 -methyl-1 ,2,3,6-tetrahydropyridin-4-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[5-methyl-4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-methoxy-2-(propan-2-yloxy)phenyl]amino}-7-phenylthieno[3,2-d]-pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-[3- (methylsulfinyl)phenyl]thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-cyanophenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 H-imidazol-1 -yl)-2-(propan-2-yloxy)phenyl]amino}-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-{methyl[2-(pyrrolidin-1 -yl)ethyl]amino}-2-(propan-2-yloxy)phenyl]amino}-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[6-(4-methylpiperazin-1 -yl)-4-(propan-2-yloxy)pyridin-3-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[6-(1 -methylpiperidin-4-yl)-4-(propan-2-yloxy)pyridin-3-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(5-fluoro-2-methoxyphenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(3-fluoro-2-methoxyphenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-[2- (methylsulfinyl)phenyl]thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[3-(dimethylamino)pyrrolidin-1 -yl]-2-(propan-2-yloxy)phenyl}amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[4-{methyl[2-(pyrrolidin-1 -yl)ethyl]amino}-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-fluoro-3-methoxyphenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -ethylpiperidin-3-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-fluorophenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1 H-pyrrol-2-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-[2-fluoro-5-(hydroxymethyl)phenyl]-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(5-methoxy-1 -methyl-1 ,2,3,6-tetrahydropyridin-4-yl)-2-(propan-2-yloxy)-phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(4-fluoro-2-methoxyphenyl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 H-imidazol-1 -yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxyphenyl)-thieno[3,2-d]pyrimidine-6-carboxamide;

2-methylpropan-2-yl 4-[5-{[6-carbamoyl-7-(2-methoxyphenyl)thieno-[3,2-d]pyrimidin-2-yl]amino}-1 -(propan-2-yl)-1 H-pyrazol-3-yl]piperidine-1 -carboxylate;

7-(2-methoxyphenyl)-2-{[2-(propan-2-yloxy)-4-(2,2,6,6-tetramethylpiperidin-4-yl)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(2,6-dimethylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(2-ethylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-thieno[3,2-d]pyrimidine-6-carboxamide;

7-(4-fluoro-2-methoxyphenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(3,5-dimethylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[2-(propan-2-yloxy)-4-(3,4,5-trimethylpiperazin-1 -yl)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[(8aR)-hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl]-2-(propan-2-yloxy)-phenyl}amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[3-(piperidin-4-yl)-1 -(propan-2-yl)-1 H-pyrazol-5-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[(3R)-1 -ethylpiperidin-3-yl]-2-(propan-2-yloxy)phenyl}amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[(3S)-1 -ethylpiperidin-3-yl]-2-(propan-2-yloxy)phenyl}amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(thiophen-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(5-fluoro-2-methoxypyridin-4-yl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-({2-(propan-2-yloxy)-4-[(2R,4S)-2-(propan-2-yl)-piperidin-4-yl]phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-({2-(propan-2-yloxy)-4-[(2R,4R)-2-(propan-2-yl)-piperidin-4-yl]phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-chlorophenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[(8aR)-hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl]-2-(propan-2-yloxy)-phenyl}amino)-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide; 7-(3-chlorophenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methylphenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1 -methyl-1 H-pyrazol-4-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2,5-dimethoxyphenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-[2-(difluoromethoxy)phenyl]-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1 H-pyrazol-4-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[3-(2-hydroxyethyl)-4-methylpiperazin-1 -yl]-2-(propan-2-yloxy)-phenyl}amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[5-methyl-4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[1 -(2-hydroxyethyl)piperidin-4-yl]-2-(propan-2-yloxy)phenyl}amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[4-(3-methoxypyridin-4-yl)-2-(propan-2-yloxy)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[6-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)pyridin-3-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[4-(1 ,2,2,6,6-pentamethylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[(2S,4S)-2-ethyl-1 -methylpiperidin-4-yl]-2-(propan-2-yloxy)phenyl}-amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[(2S,4R)-2-ethyl-1 -methylpiperidin-4-yl]-2-(propan-2-yloxy)phenyl}-amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-({2-(propan-2-yloxy)-4-[1 -(propan-2-yl)piperidin-4-yl]phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(5-fluoro-2-methoxypyridin-3-yl)-2-({2-(propan-2-yloxy)-4-[1 -(propan-2-yl)-piperidin-4-yl]phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[5-methyl-4-(1 -methylpiperidin-4-yl)-2-(propan- 2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(6-methoxypyridin-2-yl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-chlorophenyl)-2-({4-[1 -(2-hydroxyethyl)piperidin-4-yl]-2-(propan-2-yloxy)-phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[6-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)pyridin-3-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 ,7-diazaspiro[4.4]non-7-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[3-(diethylamino)pyrrolidin-1 -yl]-2-(propan-2-yloxy)phenyl}amino)-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[3-(dimethylamino)pyrrolidin-1 -yl]-2-(propan-2-yloxy)phenyl}amino)-7-(1 -methyl-1 H-pyrrol-2-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1 -methyl-1 H-pyrrol-2-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methylpyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(furan-2-yl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-[5-(aminomethyl)furan-2-yl]-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1 H-pyrrol-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[3-(dimethylamino)pyrrolidin-1 -yl]-2-(propan-2-yloxy)phenyl}amino)-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-ethoxypyridin-3-yl)-2-({2-(propan-2-yloxy)-4-[1 -(propan-2-yl)piperidin-4-yl]-phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-ethoxypyridin-3-yl)-2-{[5-methyl-4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[5-methyl-4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-ethoxypyridin-3-yl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-ethoxypyridin-3-yl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxy-5-methylpyridin-3-yl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxy-5-methylpyridin-3-yl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxy-5-methylpyridin-3-yl)-2-{[5-methyl-4-(1 -methylpiperidin-4-yl)-2- (propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1 -methyl-1 H-pyrazol-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[3-(2-methoxyethyl)-4-methylpiperazin-1 -yl]-2-(propan-2-yloxy)-phenyl}amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[4-{(3R)-3-[methyl(oxetan-3-yl)amino]piperidin-1 -yl}-2- (propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methylfuran-3-yl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(6-methoxypyridin-2-yl)-2-{[5-methyl-4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[3-(dimethylamino)pyrrolidin-1 -yl]-5-methyl-2-(propan-2-yloxy)-phenyl}amino)-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[3-(dimethylamino)pyrrolidin-1 -yl]-5-methyl-2-(propan-2-yloxy)-phenyl}amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-({3-[1 -(oxetan-3-yl)piperidin-4-yl]-1 -(propan-2-yl)-1 H-pyrazol-5-yl}amino)-7-[2- (trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxy-6-methylpyridin-3-yl)-2-{[5-methyl-4-(1 -methylpiperidin-4-yl)-2- (propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxy-6-methylpyridin-3-yl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxy-6-methylpyridin-3-yl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[3-(1 -ethylpiperidin-4-yl)-1 -(propan-2-yl)-1 H-pyrazol-5-yl]amino}-7-[2- (trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidine-6-carboxamide;

2-({4-[(3R,4S)-3-hydroxy-1 -methylpiperidin-4-yl]-2-(propan-2-yloxy)-phenyl}amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-({4-[(8S,8aS)-octahydroindolizin-8-yl]-2-(propan-2-yloxy)phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-({4-[(8R,8aS)-octahydroindolizin-8-yl]-2-(propan-2-yloxy)phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide

7-(2-methoxyphenyl)-2-{[4-(1 -methyl-1 H-pyrazol-4-yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-[(1 -methyl-2-oxo-2,3,4,5-tetrahydro-1 H-1 -benzazepin-8-yl)amino]thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[4-(2-methyl-1 H-imidazol-1 -yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[5-fluoro-4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[5-fluoro-4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[5-methyl-4-(2-methyl-1 H-imidazol-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[2-(propan-2-yloxy)-4-(1 H-1 ,2.4-triazol-1 -yl)phenyl]-amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-[(1 -phenyl-1 H-pyrazol-5-yl)amino]thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[4-(1 -methyl-1 H-pyrazol-3-yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[3-methyl-1 -(propan-2-yl)-1 H-pyrazol-5-yl]amino}-thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-fluorophenyl)-2-{[5-methyl-4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-[(1 -methyl-2-oxo-2,3,4,5-tetrahydro-1 H-1 -benzazepin-8-yl)amino]thieno[3,2-d]pyrimidine-6-carboxamide;

7-(4-fluoro-2-methoxyphenyl)-2-{[3-(piperidin-3-yl)-1 -(propan-2-yl)-1 H-pyrazol-5-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[3-cyclopropyl-1 -(propan-2-yl)-1 H-pyrazol-5-yl]amino}-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(4-fluoro-2-methoxyphenyl)-2-{[1 -(propan-2-yl)-3-(pyridin-3-yl)-1 H-pyrazol-5-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-[(1 -methyl-2-oxo-2,3,4,5-tetrahydro-1 H-1 -benzazepin-7-yl)amino]thieno[3,2-d]pyrimidine-6-carboxamide;

7-(4-fluoro-2-methoxyphenyl)-2-{[2-(propan-2-yloxy)-4-(1 H-1 ,2.4-triazol-1 -yl)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(2,4-dimethyl-1 H-imidazol-1 -yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-methoxy-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridin-3-yl)-thieno[3,2-d]pyrimidine-6-carboxamide;

2-[(3-cyclopropyl-1 -phenyl-1 H-pyrazol-5-yl)amino]-7-(2-methoxyphenyl)-thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(5,6-dihydroimidazo[1 ,2-a]pyrazin-7(8H)-yl)-2-(propan-2-yloxy)-phenyl]amino}-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -cyclopropylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -cyclopropylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(5-fluoro-2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -cyclopropylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[4-(4-methyl-1 H-imidazol-1 -yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(4-fluoro-2-methoxyphenyl)-2-[(1 -methyl-2-oxo-2,3,4,5-tetrahydro-1 H-1 -benzazepin-7-yl)amino]thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1 -oxidopyridin-2-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(1 -ethyl-1 ,7-diazaspiro[4.4]non-7-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-ethoxypyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(3,5-dimethyl-1 H-1 ,2.4-triazol-1 -yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1 -yl)-2-(propan

2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxy-6-methylpyridin-3-yl)-2-{[4-(2-methyl-1 H-imidazol-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-({4-[(4-methylpiperazin-1 -yl)methyl]-2-(propan-2-yloxy)phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxy-6-methylpyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1 -yl)-2- (propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[1 -methyl-2-oxo-6-(propan-2-yloxy)-2,3,4,5-tetrahydro-1 H-1 benzazepin-7-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[1 -methyl-2-oxo-6-(propan-2-yloxy)-2,3,4,5-tetrahydro- 1 H-1 -benzazepin-7-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[5-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)-phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[2-(propan-2-yloxy)-4-(tetrahydro-2H-pyran-4-ylamino)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(3-methoxypyridin-2-yl)-2-{[5-methyl-4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(4-hydroxypiperidin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-({4-[(1 -methylpiperidin-4-yl)amino]-2-(propan-2-yloxy)phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[1 -cyclobutyl-3-(1 -ethylpiperidin-4-yl)- 1 H-pyrazol-5-yl]amino}-7-(4-fluoro-2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-({4-[(4-methylpiperazin-1 -yl)methyl]-2-(propan-2-yloxy)phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[4-(1 -methylpyrrolidin-3-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[3-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[1 -(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)- 1 H-pyrazol-5-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[3-methyl-1 -(propan-2-yl)-1 H-pyrazol-5-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-[(5-methyl-2,3,4,5-tetrahydro-1 ,5-benzoxazepin-7-yl)amino]thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[1 -(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)-1 H-pyrazol-5-yl]amino}-7-[2- (trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[3-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[5-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-({4-[(1 -methylpiperidin-4-yl)amino]-2-(propan-2-yloxy)phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;

2-{[4-(4-ethylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridin-3 yl)thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[1 -methyl-2-oxo-8-(propan-2-yloxy)-2,3,4,5-tetrahydro-1 H-1 benzazepin-7-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxyphenyl)-2-{[1 -(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)-1 H-pyrazol-5-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[1 -methyl-2-oxo-8-(propan-2-yloxy)-2,3.4,5-tetrahydro-1 H-1 -benzazepin-7-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

7-(2-methoxypyridin-3-yl)-2-{[4-(1 -methyl-1 H-pyrazol-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;

[7-(2-methoxyphenyl)-2-{[4-(1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(2-methoxyphenyl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(2-methoxy-6-methylpyridin-3-yl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(2-ethoxypyridin-3-yl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(2-methoxypyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1 -yl)-2- (propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(2-methoxy-6-methylpyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1 -yl)-2- (propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(2-methoxy-6-methylpyridin-3-yl)-2-{[1 -(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)

1 H-pyrazol-5-yl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(2-ethoxypyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(2-methoxyphenyl)-2-{[5-methyl-4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(2-methoxy-6-methylpyridin-3-yl)-2-{[4-(1 -methyl-1 ,7-diazaspiro[4.4]non-7-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[2-{[4-chloro-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidin-6-yl]methanol;

(2-{[3-methyl-1 -(propan-2-yl)-1 H-pyrazol-5-yl]amino}-7-[2-(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidin-6-yl)methanol;

[7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[3-methyl-1 -(propan-2-yl)-1 H-pyrazol-5-yl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

(2-{[1 -(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)-1 H-pyrazol-5-yl]amino}-7-[2-(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidin-6-yl)methanol;

[7-(2-methoxyphenyl)-2-{[1 -(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)-1 H-pyrazol-5 yl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(5-fluoro-2-methoxyphenyl)-2-{[3-methyl-1 -(propan-2-yl)-1 H-pyrazol-5-yl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(5-fluoro-2-methoxyphenyl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

(2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}-7-[2- (trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidin-6-yl)methanol;

[7-(2-methoxypyridin-3-yl)-2-{[4-(1 -methyl-1 H-pyrazol-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(2-methoxyphenyl)-2-{[4-(1 -methyl-1 H-pyrazol-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[2-{[5-methyl-4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}-7-(6-methylpyridin-3-yl)thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(2-methoxypyridin-3-yl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

[7-(2-methoxyphenyl)-2-{[4-(1 -methylpyrrolidin-3-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;

2-(2-{[2-methoxy-4-(4-methylpiperazin-1 -yl)phenyl]amino}-7-phenylthieno[3,2-d]pyrimidin-6-yl)propan-2-ol;

2-[2-{[2-methoxy-4-(4-methylpiperazin-1 -yl)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidin-6-yl]propan-2-ol; and

2-[7-(4-fluoro-2-methoxyphenyl)-2-{[2-methoxy-4-(4-methylpiperazin-1 -yl)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]propan-2-ol;

or a pharmaceutically acceptable salt thereof.

13. A process for preparing a compound according to Claim 1 , wherein a thienopyrimidine of formula (II):

wherein

R7 is an aryl or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (d-C6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

R8 is a halo(CrC6)alkyl group;

n is 1 or 2;

R16 is a (CrC6)alkoxy group;

is reacted

a) with a compound of formula (1Mb):

HO (" lb)

HN

I

R

wherein

R is a phenyl or heteroaryl group substituted with R1 , R'1 , R2 and R3;

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, (CrC6)alkoxy, (C3-C7)cycloalkyl and aryl, these groups being optionally substituted with one or several substituents selected, independently in each instance, from: amino, hydroxyl, thiol, halogen, (CrC6)alkyl, (CrC6)alkoxy, (CrC6)alkylthio, (C C6)alkylamino, aryloxy, aryl(CrC6)alkoxy, cyano, halo(CrC6)alkyl, carboxyl and carboxy(CrC6)alkyl;

R'1 is a hydrogen atom or a (CrC6)alkoxy group;

R2 is selected from:

- a hydrogen atom, a halogen atom or a (CrC6)alkyl, (C3-C7)cycloalkyl or (C C6)alkoxy group;

- a heterocycloalkyl, heterocycloalkyl-CH2- or heteroaryl group;

these heterocycloalkyl, heterocycloalkyl-CH2- and heteroaryl groups being optionally substituted with one or several substituents selected, independently in each instance, from: (CrC6)alkyl, (C3-C7)cycloalkyl, (CrC6)alkoxy, heterocycloalkyl, carboxy(CrC6)alkyl, NR4R5 and OR4;

said (CrC6)alkyl group being optionally substituted with a halogen atom or a (CrC6)alkoxy, heterocycloalkyl, NH2 or OH group; and

- an NRaRb group, where Ra and Rb are, independently of one another:

. a hydrogen atom;

. a heterocycloalkyl group, said heterocycloalkyl group being optionally substituted with a (d-C6)alkyl group; or

. a (CrC6)alkyl group, said (CrC6)alkyl group being optionally substituted with an NR4R5 group;

wherein:

R4 and R5 each is, independently of one another, a hydrogen atom, a (C C6)alkyl group or a heterocycloalkyl group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;

R3 is a hydrogen atom, a halogen atom or a (CrC6)alkyl group;

wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyl ring fused with the phenyl bearing them, this heterocycloalkyl being optionally substituted with one or several substituents selected, independently in each instance, from: an oxo group and a (CrC6)alkyl group;

b) then step a) is followed:

- either by a step of treating the mixture obtained with an aqueous ammonia solution so as to obtain the compounds of formula (I) wherein R6 is -CONH2;

- or by a step of reducing the mixture obtained with a reducing agent in a solvent, which makes it possible to obtain the compounds of formula (I) in which R6 is a -C(Ra)(Rp)(OH) group wherein RQ and Rp are hydrogen atoms;

- or by a step of treating the mixture obtained with an excess of an organometallic derivative (RQMgX or RpLi for example) in a solvent, which makes it possible to obtain the compounds of formula (I) wherein R6 is a -C(Ra)(Rp)(OH) group where Ra and Rp are identical and are a (CrC6)alkyl group.

14. A process for preparing a compound according to Claim 1 and wherein R6 is -CONH2,

wherein a compound of formula (XII):

in which

R7 is an aryl or heteroaryl group, this group being optionally substituted with at least one substituent selected from: cyano, halogen, (d-C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (CrC6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

R8 being a halo(CrC6)alkyl group;

n is 1 or 2;

is reacted

with a compound of formula (1Mb)

HO

HN

I

R (1 Mb)

wherein

R is a phenyl or heteroaryl group substituted with R1 , R'1 , R2 and R3;

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, (CrC6)alkoxy, (C3-C7)cycloalkyl and aryl, these groups being optionally substituted with one or several substituents selected, independently in each instance, from: amino, hydroxyl, thiol, halogen, (CrC6)alkyl, (CrC6)alkoxy, (CrC6)alkylthio, (C

C6)alkylamino, aryloxy, aryl(CrC6)alkoxy, cyano, halo(CrC6)alkyl, carboxyl and carboxy(CrC6)alkyl;

R'1 is a hydrogen atom or a (d-C6)alkoxy group;

R2 is selected from:

- a hydrogen atom, a halogen atom or a (CrC6)alkyl, (C3-C7)cycloalkyl or (C C6)alkoxy group;

- a heterocycloalkyi, heterocycloalkyl-CH2- or heteroaryl group;

these heterocycloalkyi, heterocycloalkyl-CH2- and heteroaryl groups being optionally substituted with one or several substituents selected, independently in each instance, from: (CrC6)alkyl, (C3-C7)cycloalkyl, (CrC6)alkoxy, heterocycloalkyi, carboxy(CrC6)alkyl, NR4R5 and OR4;

said alkyl group being optionally substituted with a halogen atom or a (C C6)alkoxy, heterocycloalkyi, NH2 or OH group;

wherein:

R4 and R5 each is, independently of one another, a hydrogen atom, a (C C6)alkyl group or a heterocycloalkyi group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; and

- an NRaRb group, where Ra and Rb are, independently of one another:

. a hydrogen atom;

. a heterocycloalkyi group, said heterocycloalkyi group being optionally substituted with a (CrC6)alkyl group; or

. a (CrC6)alkyl group, said alkyl group being optionally substituted with an NR4R5 group;

wherein:

R4 and R5 each is, independently of one another, a hydrogen atom, a (C C6)alkyl group or a heterocycloalkyi group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; and

R3 is a hydrogen atom, a halogen atom or a (CrC6)alkyl group;

wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyi ring fused with the phenyl bearing them, this heterocycloalkyi being optionally substituted with one or several substituents selected, independently in each instance, from: an oxo group and a (d-C6)alkyl group;

in the presence of an organic or inorganic base in a polar aprotic solvent.

15. A process for preparing a compound according to Claim 1 and in which R6 is a -C(Ra)(Rp)(OH) group, wherein RQ and Rp are, independently of one another, a hydrogen atom or a (CrC6)alkyl group, or together form, with the carbon atom which bears them, a 3- to 5-membered carbocycle,

wherein a compound of formula XIV):

(XIV)

n = 1 ,2

wherein

RQ and Rp are, independently of one another, a hydrogen atom or a (CrC6)alkyl group, or together form, with the carbon atom which bears them, a 3- to 5-membered carbocycle;

R7 is an aryl or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (Ci-C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (CrC6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with at least one halogen atom or an NH2 or OH group; R8 is a halo(CrC6)alkyl group;

n is 1 or 2;

is reacted

with a compound of formula (1Mb)

HO

HN

I

R (1Mb)

wherein

R is a phenyl or heteroaryl group substituted with R1 , R'1 , R2 and R3;

R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, (CrC6)alkoxy, (C3-C7)cycloalkyl and aryl, these groups being optionally substituted with one or several substituents selected, independently in each instance, from: amino, hydroxyl, thiol, halogen, (d-C6)alkyl, (CrC6)alkoxy, (CrC6)alkylthio, (C C6)alkylamino, aryloxy, aryl(CrC6)alkoxy, cyano, halo(CrC6)alkyl, carboxyl and carboxy(CrC6)alkyl;

R'1 is a hydrogen atom or a (CrC6)alkoxy group;

R2 is selected from:

- a hydrogen atom, a halogen atom or a (CrC6)alkyl, (C3-C7)cycloalkyl or (C C6)alkoxy group;

- a heterocycloalkyl, heterocycloalkyl-CH2- or heteroaryl group;

these heterocycloalkyl, heterocycloalkyl-CH2- and heteroaryl groups being optionally substituted with one or several substituents selected, independently in each instance, from: (CrC6)alkyl, (C3-C7)cycloalkyl, (CrC6)alkoxy, heterocycloalkyl, carboxy(CrC6)alkyl, NR4R5 and OR4;

said alkyl group being optionally substituted with a halogen atom or a (C C6)alkoxy, heterocycloalkyl, NH2 or OH group; and

wherein:

R4 and R5 each is, independently of one another, a hydrogen atom, a (C C6)alkyl group or a heterocycloalkyl group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; and

- an NRaRb group, where Ra and Rb are, independently of one another:

. a hydrogen atom;

. a heterocycloalkyi group, said heterocycloalkyi group being optionally substituted with a (d-C6)alkyl group; or

. a (CrC6)alkyl group, said alkyl group being optionally substituted with an NR4R5 group;

wherein:

R4 and R5 each is, independently of one another, a hydrogen atom, a (C C6)alkyl group or a heterocycloalkyi group;

or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; and

R3 is a hydrogen atom, a halogen atom or a (CrC6)alkyl group;

wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyi ring fused with the phenyl bearing them, this heterocycloalkyi being optionally substituted with one or several substituents selected, independently in each instance, from: an oxo group and a (CrC6)alkyl group;

in the presence of an organic or inorganic base in a polar aprotic solvent.

16. A compound of formula (II):

wherein:

R7 is an aryl group or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (CrC6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

R8 is a halo(CrC6)alkyl group;

n is 1 or 2;

R16 is a (CrC6)alkoxy group;

or a pharmaceutically acceptable salt thereof.

17. A compound of formula (XII):

(XII)

wherein:

R7 is an aryl or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (C C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (CrC6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

R8 is a halo(CrC6)alkyl group;

n is equal to 1 or to 2;

or a pharmaceutically acceptable salt thereof.

18. A compound f formula (XIV):

(XIV)

n = 1 ,2

wherein:

Re and Rp are, independently of one another, a hydrogen atom or a (d-C6)alkyl group or together form, with the carbon atom which bears them, a 3- to 5-membered carbocycle;

R7 is an aryl or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (Ci-C6)alkyl, OR'4, CH2OH, CH2NH2, S(0)nR'4, R8 and OR8;

wherein:

R'4 is a hydrogen atom or a (CrC6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;

R8 is a halo(CrC6)alkyl group;

n is 1 or 2;

or a pharmaceutically acceptable salt thereof.

19. A medicament comprising a compound according to any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition, comprising a compound according to any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient.

21. A compound according to any one of Claims 1 to 12, for use in treating cancer.